Utilins, a new tuberculosis drug of Laimei pharmaceutical, passed GMP on-site inspection

Laimei Pharmaceutical Co., Ltd passed the proposal of acquiring the equity of Chengdu Jinxing Pharmaceutical Co., Ltd which is mainly engaged in Utilins preparation by high vote Qiu Yu, chairman of Laimei Pharmaceutical Co., Ltd., communicated with the reporter that the on-site inspection of new Utilins GMP has been completed and will enter the administrative approval process according to the process Industry analysis, which means the company's Utilins preparation is expected to launch in the first half of this year It is understood that Utilins is a kind of imported medicine, which is a multifunctional immunoenhancer Its main component is inactivated Mycobacterium, belonging to Mycobacterium It is a kind of non pathogenic bacteria to human beings It mainly regulates the immune function of the body by affecting the immune response, so as to achieve the purpose of treatment News extension > > on May 7, 2013, the board of directors of Laimei Pharmaceutical Co., Ltd approved the proposal on the establishment of Sino foreign cooperative enterprises and foreign investment According to the announcement, the company plans to add 200 million yuan to Chengdu Jinxing Health Pharmaceutical Co., Ltd within two years After the capital increase is completed, the company will hold 60% of the shares of the latter Laimei pharmaceutical said that "timely intervention in the field of biopharmaceutical will be conducive to further improving the company's overall competitiveness and profitability, and accelerating the pace of the company's growth and strength." Independent directors of the company also believe that after the completion of this transaction, "the company's products will be enriched, its business will be expanded, its scale will be expanded, its competitiveness will be strengthened and its profitability will be improved, which is in line with the company's development plan and the interests of all shareholders" According to the announcement, the main product of Jinxing pharmaceutical is the immunomodulator - Mycobacterium phlei f.u.36 injection (hereinafter referred to as "ubelins"), which is mainly used for auxiliary treatment of pulmonary and extrapulmonary tuberculosis Utilins is imported from Germany by Jinxing Pharmaceutical Co., Ltd and is exclusively produced and sold in China The data shows that the curative effect of Utilins products has been widely recognized by the society and has entered the national medical insurance catalogue, which has a large market space Previously, the production of utillins injection of Jinxing pharmaceutical was limited by the restriction of the State Food and Drug Administration on the quantity of imported raw bacterial solution (one-time import and one-time approval) According to the data, in 2009, the operating revenue of Jinxing pharmaceutical was about 31.79 million yuan, the net profit was nearly 15 million yuan, and the net interest rate was close to 50% However, Venus pharmaceutical lost money in 2012 and the first two months of this year In response, the company explained that this was "due to the impact of the Wenchuan earthquake in 2008, the original shareholders lack of reconstruction funds, resulting in Jinxing pharmaceutical industry has been in a state of shutdown since August 2009" Laimei pharmaceutical further said that after the completion of this capital increase, Jinxing pharmaceutical will complete the construction and transformation of production facilities and equipment and pass GMP certification, so as to realize the whole process production of Utilins in China After the breakthrough of its production and sales bottleneck, it is expected that the production and sales volume of Jinxing pharmaceutical industry in the future will have a larger growth than the previous normal production year Previously, a researcher in the pharmaceutical industry of huitianfu fund company disclosed to reporters that "Utilins" is expected to become a new heavyweight product of the company after localization After cultivation, the market space is expected to reach hundreds of millions of yuan.